Solanesol vaccine adjuvants and methods of preparing same
US12285483B2 · kind B2 · utility
0Cited by
0References
23Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Oct 16, 2021 |
| Grant date | Apr 29, 2025 |
| Priority date | — |
| Expiry date | Oct 16, 2041 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/55566
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This disclosure describes the use of solanesol as an adjuvant in vaccine compositions, as well as related prophylactic and therapeutic methods. Solanesol may be used to replace squalene in vaccine compositions with similar or superior immunostimulatory effects. Solanesol, which is solid at room temperature, may be formulated for use in vaccine compositions by heating above its melting temperature in an aqueous solution to form a dispersion.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.